See more : PT Agro Yasa Lestari Tbk (AYLS.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Lixte Biotechnology Holdings, Inc. (LIXT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lixte Biotechnology Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Nitta Corporation (5186.T) Income Statement Analysis – Financial Results
- Aquaron Acquisition Corp. (AQUNR) Income Statement Analysis – Financial Results
- Hays plc (HAS.L) Income Statement Analysis – Financial Results
- Marvion Inc. (MVNC) Income Statement Analysis – Financial Results
- Waja Company (9560.SR) Income Statement Analysis – Financial Results
Lixte Biotechnology Holdings, Inc. (LIXT)
About Lixte Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 898.10K | 1.35M | 1.74M | 1.22M | 820.91K | 40.70K | 467.26K | 1.30M | 2.09M | 1.12M | 879.89K | 1.01M | 1.33M | 445.54K | 496.52K | 608.73K | 423.83K | 150.10K | 0.00 |
| General & Administrative | 4.19M | 4.96M | 4.98M | 2.01M | 1.67M | 2.10M | 1.34M | 833.78K | 754.44K | 1.29M | 494.96K | 1.09M | 533.45K | 436.14K | 1.05M | 664.20K | 1.23M | 299.42K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.19M | 4.96M | 4.98M | 2.01M | 1.67M | 2.10M | 1.34M | 833.78K | 754.44K | 1.29M | 494.96K | 1.09M | 533.45K | 436.14K | 1.05M | 664.20K | 1.23M | 299.42K | 32.87K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 33.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 74.00K | 0.00 | 0.00 | 0.00 | 0.00 | 128.00 | 615.00 | 592.00 | 462.00 | 0.00 |
| Operating Expenses | 5.09M | 6.31M | 6.72M | 3.27M | 2.49M | 2.14M | 1.81M | 2.13M | 2.85M | 2.40M | 1.37M | 2.11M | 1.87M | 881.68K | 1.55M | 1.27M | 1.66M | 449.98K | 32.87K |
| Cost & Expenses | 5.09M | 6.31M | 6.72M | 3.27M | 2.49M | 2.14M | 1.81M | 2.13M | 2.85M | 2.40M | 1.37M | 2.11M | 1.87M | 881.68K | 1.55M | 1.27M | 1.66M | 449.98K | 32.87K |
| Interest Income | 1.25K | 11.20K | 626.00 | 5.23K | 49.72K | 4.92K | 1.38K | 183.00 | 78.00 | 66.00 | 3.00 | 8.00 | 125.00 | 1.43K | 155.00 | 3.26K | 10.55K | 11.90K | 0.00 |
| Interest Expense | 0.00 | 8.88K | 7.41K | 3.67K | 0.00 | 4.92K | 1.38K | 183.00 | 78.00 | 66.00 | 3.00 | 8.00 | 125.00 | 1.43K | 1.23K | 1.23K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.09M | 6.31M | 6.72M | 3.27M | 2.49M | 2.14M | 1.81M | 2.13M | 205.77K | 363.11K | 3.00 | 8.00 | 199.84K | 0.00 | 128.00 | 615.00 | 592.00 | 462.00 | 0.00 |
| EBITDA | 3.21K | -1.05K | -7.95K | 1.56K | -2.49M | 4.92K | 1.38K | 183.00 | -2.44M | -2.40M | -1.37M | -3.58M | -1.87M | -881.68K | -1.55M | -1.27M | -1.65M | -561.62K | -32.87K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,220.32% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -5.09M | -6.31M | -6.72M | -3.27M | -2.49M | -2.14M | -1.81M | -2.13M | -2.65M | -2.40M | -1.37M | -2.11M | -1.87M | -881.68K | -1.55M | -1.27M | -1.66M | -499.98K | -32.87K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,323.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.21K | -1.05K | -7.95K | 1.56K | 49.72K | 4.92K | 1.38K | 183.00 | -205.70K | -363.05K | 3.00 | -1.47M | -199.71K | 1.43K | -1.08K | 2.03K | 10.55K | -38.10K | 0.00 |
| Income Before Tax | -5.09M | -6.31M | -6.73M | -3.26M | -2.44M | -2.13M | -1.81M | -2.13M | -2.85M | -2.77M | -1.37M | -3.58M | -2.07M | -880.25K | -1.55M | -1.27M | -1.65M | -488.08K | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,426.05% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -7.82K | 6.79K | -1.56K | -49.72K | -9.85K | -1.81K | -2.13K | -78.00 | -66.00 | 0.00 | -8.00 | -125.00 | 0.00 | 0.00 | 0.00 | 0.00 | 38.10K | 32.87K |
| Net Income | -5.09M | -6.30M | -6.74M | -3.26M | -2.39M | -2.13M | -1.81M | -2.13M | -2.85M | -2.77M | -1.37M | -3.58M | -2.07M | -880.25K | -1.55M | -1.27M | -1.65M | -488.08K | -32.87K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,426.05% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.66 | -39.85 | -5.00 | -2.89 | -2.14 | -2.18 | -1.94 | -2.68 | -3.66 | -3.74 | -1.98 | -5.52 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -2.66 | -39.85 | -5.00 | -2.89 | -2.14 | -2.18 | -1.94 | -2.68 | -3.66 | -3.74 | -1.98 | -5.51 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 1.91M | 158.20K | 1.35M | 1.13M | 1.12M | 979.94K | 930.00K | 797.00K | 779.00K | 740.00K | 693.00K | 649.00K | 586.16M | 578.94M | 488.64M | 465.41M | 445.13M | 379.17M | 45.00M |
| Weighted Avg Shares Out (Dil) | 1.92M | 158.20K | 1.35M | 1.13M | 1.12M | 979.94K | 930.29K | 797.93K | 779.89K | 740.09K | 693.05K | 649.76K | 586.16M | 578.94M | 488.64M | 465.41M | 445.13M | 379.17M | 45.00M |
LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”
Recent Findings Relate to LIXTE's Lead Clinical Compound, LB-100, to be Presented at Workshop on May 9 and 10 at Harvard's Dana Farber Cancer Institute in Boston
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
-- Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers -- PASADENA, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a...
Professor René Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and American Associations for Cancer Research
Conference In Dublin, Ireland on February 27 - 29, 2024 Focuses on How to Bring Basic Science Discoveries to the Clinic
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
Agreement Focuses on Combining LIXTE's LB-100 with Various Innovative Cancer Immunotherapies PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”) today announced the signing of an exclusive patent license...
First Patient Dosed with LIXTE's LB-100 and GSK's Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial
PASADENA, CA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”), today announced the dosing of the first patient in a Phase 1b/2 clinical trial to assess whether adding LIXTE's LB-100...
LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations
PASADENA, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy benefit, today provided...
LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach
PASADENA, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, today announced the passing of...
LIXTE Appoints Bas van der Baan as President and Chief Executive Officer
Biotechnology V eteran Bas van der Baan B rings P recision O ncology E xpertise ; Founder John S . Kovach Named Executive Chairman
LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE's First-in-Class PP2A Inhibitor, LB-100, Plus GSK's Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer
The Phase 1b Clinical Trial Focuses on Assessing the Safety and Efficacy of the Two-Drug Combination in a Cancer Associated with Longer Survival to Immunotherapy When Genetically Deficient in PP2A
LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules
PASADENA, CA, July 20, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”) today announced the closing of its previously announced registered direct offering of 583,334 shares of common stock (or common...
Source: https://incomestatements.info
Category: Stock Reports